SCHEMBL5439749

SCHEMBL5439749

O=C(Cn1cnc2ccccc21)Nc1ccc(-c2cccc(Cl)c2)cc1.O=C(Cn1cnc2ccccc21)Nc1ccc(-c2ccccc2Cl)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.57
HTT P42858 3/20 0.54
MGLL Q99685 1/20 0.54
F2 P00734 4/20 0.53
F10 P00742 4/20 0.53
PRSS1 P07477 3/20 0.53
LMNA P02545 1/20 0.52
L3MBTL1 Q9Y468 2/20 0.51
PKM P14618 1/20 0.51
ORAI1 Q96D31 1/20 0.47
NPC1 O15118 3/20 0.47
MEN1 O00255 2/20 0.47
ALDH1A1 P00352 2/20 0.47
POLB P06746 2/20 0.47
RAB9A P51151 2/20 0.47
KMT2A Q03164 2/20 0.47
MCL1 Q07820 1/20 0.47
KDM4E B2RXH2 1/20 0.47
MAPT P10636 1/20 0.45
MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1035306 0.93 SMN1; SMN2 (0.64) SMN1; SMN2HTTMGLLF2F10
SCHEMBL1036943 0.91 MGLL (0.62) SMN1; SMN2HTTMGLLF2F10
SCHEMBL1037979 0.83 SMN1; SMN2 (0.64) SMN1; SMN2HTTMGLLF2F10
SCHEMBL1038642 0.82 MGLL (0.70) SMN1; SMN2HTTMGLLF2F10
SCHEMBL1037469 0.79 SMN1; SMN2 (0.69) SMN1; SMN2HTTMGLLF2F10
SCHEMBL1037100 0.79 SMN1; SMN2 (0.61) SMN1; SMN2HTTMGLLF2F10
SCHEMBL5427213 0.79 SMN1; SMN2 (0.67) SMN1; SMN2HTTMGLLF2F10
Hydrochloric Acid SCHEMBL1081045 0.78 SMN1; SMN2 (0.67) SMN1; SMN2HTTMGLLF2F10
SCHEMBL5438418 0.78 SMN1; SMN2 (0.53) SMN1; SMN2HTTMGLLF2F10
SCHEMBL1037695 0.77 SMN1; SMN2 (0.67) SMN1; SMN2HTTMGLLF2F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070112034-A1 2-(benzimidazol-1-yl)-acetamide bisaryl derivatives AKZO NOBEL N.V. (NL) 2007-05-17 US claimed
US-20070112034-A1 2-(benzimidazol-1-yl)-acetamide bisaryl derivatives AKZO NOBEL N.V. (NL) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112034-A1 2-(benzimidazol-1-yl)-acetamide bisaryl derivatives TRPV1, TRPV3, TRPV2 SMN1; SMN2 3054/4885HTT 2439/4885MGLL 3091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.